← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2003Last known activity
Mar 5, 2018
Defunct as of Oct 10, 2023
Timeline
1990s
- Jun 1, 1999
NewLink Genetics Inc— Founded
2010s
- Jan 7, 2011
BioProtection Systems Corporation— Acquired - Sep 30, 2019
Lumos Pharma— Acquired
2020s
- Oct 10, 2023
NewLink Genetics Inc— Defunct
Drugs by trial phase (32 distinct, 46 trials)
Phase 3 (13 own, 2 via acquisition)
Phase 2 (14 own, 0 via acquisition)
Phase 1 (1 own, 2 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Large Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Ependymoma
- Glioblastoma
- Glioma
- Gliosarcoma
- Hemorrhagic Fever, Ebola
- Kidney Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Medulloblastoma
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT03852446Study directorEarly Phase 1Mar 5, 2018
- NCT03852446Lead sponsorEarly Phase 1Mar 5, 2018
- NCT03301636Lead sponsorPhase 2/Phase 3Dec 8, 2017
- NCT03372239Lead sponsorPhase 1Nov 21, 2017
- NCT03372239Study directorPhase 1Nov 21, 2017
- NCT03164603Lead sponsorPhase 1May 1, 2017
- NCT02835729Lead sponsorPhase 1/Phase 2Jul 1, 2016
- NCT02460367Study directorPhase 1/Phase 2Jan 1, 2016
- NCT02460367Lead sponsorPhase 1/Phase 2Jan 1, 2016
- NCT02502708Lead sponsorPhase 1Oct 1, 2015
- NCT02648711Lead sponsorPhase 1Oct 1, 2015
- NCT02502708Study directorPhase 1Oct 1, 2015
- NCT02648711Study chairPhase 1Oct 1, 2015
- NCT02389985Lead sponsorPhase 1/Phase 2Jul 1, 2015
- NCT02035358Lead sponsorPhase 1May 1, 2015
Details
- Founded
- Ames, IA, US Jun 1, 1999
- Last known activity
- Mar 5, 2018